Literature DB >> 22884380

World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation.

James C Fang1, Teresa DeMarco, Michael M Givertz, Barry A Borlaug, Gregory D Lewis, J Eduardo Rame, Mardi Gomberg-Maitland, Srinivas Murali, Robert P Frantz, Dana McGlothlin, Evelyn M Horn, Raymond L Benza.   

Abstract

Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council.
Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884380     DOI: 10.1016/j.healun.2012.06.002

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  58 in total

1.  Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis.

Authors:  Dimitry Schewel; Jury Schewel; Julia Martin; Lisa Voigtländer; Christian Frerker; Peter Wohlmuth; Thomas Thielsen; Karl-Heinz Kuck; Ulrich Schäfer
Journal:  Clin Res Cardiol       Date:  2014-11-04       Impact factor: 5.460

Review 2.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

3.  Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions.

Authors:  Jennifer E Ho; Emily K Zern; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Giovanna A Zampierollo; Petr Jarolim; Paul P Pappagianopoulos; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis
Journal:  Circulation       Date:  2019-05-28       Impact factor: 29.690

4.  ECG-gated computed tomography to assess pulmonary capillary wedge pressure in pulmonary hypertension.

Authors:  Nancy Sauvage; Emilie Reymond; Adrien Jankowski; Marion Prieur; Christophe Pison; Hélène Bouvaist; Gilbert R Ferretti
Journal:  Eur Radiol       Date:  2013-06-09       Impact factor: 5.315

5.  Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers.

Authors:  Meredith E Pugh; Anna R Hemnes; Aaron Trammell; John H Newman; Ivan M Robbins
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

Review 6.  Management of pulmonary hypertension and right heart failure in the intensive care unit.

Authors:  Jonathan Grinstein; Mardi Gomberg-Maitland
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

7.  Left Heart Disease and Pulmonary Hypertension: Controversy Redefined.

Authors:  Myung H Park
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

8.  Pulmonary hypertension: a long-term risk stratifier in primary mitral regurgitation.

Authors:  Mi-Jeong Kim; Hae Ok Jung
Journal:  Ann Transl Med       Date:  2016-12

9.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

10.  Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rebecca R Vanderpool; Melissa Saul; Mehdi Nouraie; Mark T Gladwin; Marc A Simon
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.